Menu Search
Equities

Northwest Biotherapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0K95:LSE

Northwest Biotherapeutics Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta-0.8324
Data delayed at least 20 minutes, as of Mar 26 2021.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its platform technology, DCVax, is a personalized immune therapy that uses a patient’s own dendritic cells, or DCs, the master cells of the immune system, as the therapeutic agent. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, and others.

  • Revenue in USD (TTM)937.00k
  • Net income in USD-91.22m
  • Incorporated1998
  • Employees25.00
  • Location
    Northwest Biotherapeutics IncSUITE 800, 4800 MONTGOMERY LANEBETHESDA 20814United StatesUSA
  • Phone+1 (240) 497-9024
  • Fax+1 (302) 636-5454
  • Websitehttps://nwbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NWBO:QBB since
announced		Transaction
value
Advent Bioservices LtdAnnounced27 Aug 202527 Aug 2025Announced6.25%--
Data delayed at least 15 minutes, as of Feb 06 2026 20:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.